Batch 001 - Live Allocation

Next Release: Aug 2026

Vivre Labs

Institutional Longevity

Catalogue
Single-vial Blends · one injection
Clinical Details

- Peptides -

- Single-vial Blends -

- Goals -

- Clinical Reference -

- Guides -

- Integrity -

◇ Compound Reference

SEXUAL HEALTHFDA-Approved

PT-141

Bremelanotide / Vylessi · 10mg

Status

FDA-Approved

Route

SubQ

Half-life

Class

Melanocortin agonist

MechanismMC4R / MC3R Activation

Cohort58 active prescriptions

Educational reference only - not a prescription or dosing recommendation. Some compounds are investigational or used off-label; suitability, dose, and monitoring are determined by your supervising physician. See Informed Consent & Disclaimer.

V-Series Member

$75 USD/vial

À-la-carte: $85 USD/vial · Save 12%

Vials per allocation

Member total (1×)$75

À-la-carte total$85

Flat per-vial pricing. Quantity is allocated and dispensed within your physician-supervised protocol - not a direct sale.

What this is

Central nervous system melanocortin receptor agonist. Addresses hypoactive sexual desire via neurological pathways, not vascular mechanisms.

Bremelanotide / Vylessi · 10mg per vial · dispensed after a physician review.

◇

Janoshik Verified

HPLC + MS purity, every batch

Independent third-party lab

⬡

COA Per Batch

Lot-level certificates published

Labeled vs actual mg disclosed

⊙

Protocol Reviewed

Used in V-Series clinical stacks

Phase 1 supervision onboarding

PT-141 · Sexual health

◆ Certificate of Analysis · PT-141

JANOSHIK ANALYTICALHPLC + MS · Independent third-party

Lot-specific COAs for PT-141 are published with each batch release. Sample certificates available on request via partnerships@vivrelabs.com.

◉

Clinical Overview

PT-141

PT-141 (Bremelanotide, brand name Vyleesi) is a 7-amino-acid synthetic melanocortin receptor agonist. FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women.

Notable for acting through central nervous system pathways rather than vascular mechanisms.

✦

MC4R Activation

Central melanocortin-4 receptor agonist.

❖

Neural Pathway

Acts through CNS pathways, distinct from PDE5 inhibitors.

◈

Approved Analog

Bremelanotide is FDA-approved for a specific indication.

◈

Mechanism

How It Works

Activates melanocortin-4 receptors (MC4R) in the central nervous system. Drives sexual response through neural pathways, distinct from PDE5 inhibitors (sildenafil class) which act on vascular smooth muscle.

Mechanism & evidence - the honest frame

Regulatory & evidence frame: bremelanotide is FDA-approved as Vyleesi (2019) for ONE specific indication - premenopausal women with acquired, generalised hypoactive sexual desire disorder (HSDD) - based on two 24-week randomised, double-blind, placebo-controlled trials (n=1,247). It is a central melanocortin (MC4R) agonist acting on desire pathways in the brain, NOT a blood-flow/PDE5 mechanism. Honest reading of the data: the effect is real but modest, and the FDA label explicitly states it is NOT indicated to enhance sexual performance. Any use outside premenopausal-female HSDD (including in men) is off-label. Tolerability matters: in the trials ~18% discontinued for adverse effects vs 2% on placebo, most commonly nausea (~8%). SAFETY: contraindicated in uncontrolled hypertension or known cardiovascular disease - it causes a transient rise in blood pressure after each dose (usually resolving within ~12 hours). Use is a physician decision with cardiovascular screening; Vivre does not frame this as performance enhancement.

✚

Patient Bloodwork Guide

Bloodwork for Cognitive & Neuro Protocols

Nootropic / neuro - Semax, Selank, DSIP, Oxytocin, PT-141, Kisspeptin

These protocols target cognition, mood, stress regulation, and sleep. Their effects are mostly subjective and behavioral, so monitoring leans on functional and stress-axis markers more than a classic blood panel - the aim is to confirm benefit without disrupting your stress hormones or sleep architecture.

Incremental approach. These are low-dose, often short-course or as-needed protocols. Vivre tracks how you actually feel and function alongside a light marker panel, rather than chasing numbers - the subjective response is the primary signal here.

Stress axis & recovery

Cortisol rhythm (AM/PM)Confirms the protocol is calming the stress axis, not over-stimulating it. The key safety/efficacy marker for this group.

HRV (heart-rate variability)A non-blood measure of nervous-system balance and recovery - rises as stress regulation improves.

Brain & vascular health

HomocysteineElevated levels are linked to cognitive risk; a useful baseline to optimize.

BDNFA marker tied to neuroplasticity - context for neuro-supportive protocols (where testing is available).

Routine safety

CBC & CMPStandard blood count, liver, and kidney panels.

When the tests happen

BaselineCortisol rhythm, HRV, homocysteine, plus how you rate mood/focus/sleep.

Month 1HRV and a subjective check-in - is it helping, any over-stimulation?

Month 3Repeat cortisol rhythm and HRV to confirm a sustained, healthy direction.

Educational only - not medical advice or a dosing instruction. Your physician orders the tests, sets your dose, interprets results, and decides if a protocol is right for you. See the Informed Consent & Disclaimer for full terms.

⊞

Technical Profile

Measurable Properties

Class	Melanocortin-receptor agonist (bremelanotide)
Mechanism	MC receptor agonism (incl. MC4R); central effect on sexual response - characterised
Terminal half-life	~2–3 hours order
Metabolism	Peptidase degradation
Evidence base	Strong - approved-class agent for a specific indication
Regulatory status	Approved-class for a specific indication; physician-supervised use only

Certificate of Analysis (per batch)

Analytical method: UHPLC-MS. Batch COA available on request - link to be populated per shipment.

COA link - pending per batch

Approved-class agent, well-characterised. Educational only; treatment physician-determined.

Clinical Literature

Peer-Reviewed References

Bremelanotide for Hypoactive Sexual Desire Disorder in Premenopausal Women: A Randomized, Placebo-Controlled Trial (RECONNECT)

Kingsberg SA, Clayton AH, Portman D, et al. · 2019 · Obstetrics & Gynecology 2019;134:899–908

▾

Findings

Phase 3 RCT supporting the FDA approval of bremelanotide for hypoactive sexual desire disorder in premenopausal women. Demonstrated statistically significant improvements in desire and decreased distress versus placebo. Adverse events were predominantly mild-to-moderate, with nausea, flushing, and headache most common.

View on publisher ↗

PT-141 / bremelanotide is approved-class for its specific indication. Use outside this indication is off-label and physician-supervised at Vivre.

◇

Clinical Applications

Indications

Hypoactive sexual desire disorder
Sexual dysfunction unresponsive to PDE5 inhibitors
Female sexual interest restoration

⊙

Pharmacokinetics

Half-Life & Duration of Action

Half-life is how long a compound stays at active plasma concentration in your body. Most peptides in this catalogue have short plasma half-lives - they clear from your bloodstream within hours, sometimes minutes. The long-half-life compounds in this catalogue are the approved-class incretins (Tirzepatide, Semaglutide, Retatrutide), which are designed for once-weekly dosing - that's the molecular engineering choice that makes weekly dosing work.

Plasma Half-Life

~2.7 hours (FDA-approved pharmacokinetic profile for Vyleesi formulation).

Why this matters for you

If you don't tolerate a compound or need to discontinue a protocol, short-half-life peptides are out of your bloodstream within hours - not days or weeks. That said, the biological effects they initiate (tissue repair signalling, mitochondrial signalling, gene expression changes) often persist longer than the peptide itself, through downstream cellular cascades. This is normal peptide pharmacology and is important context - the molecule clears fast, but the biology takes longer to wind down.

Evidence Base

FDA-approved with clinical trial data.

Dosing protocols, administration frequency, and titration schedules are physician-determined at consultation - not published on these public pages. Vivre maintains a separate internal clinical reference for treating physicians.

READY TO PROCEED

Start with the Biological Audit

PT-141 is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.

$75 USD/vial

PT-141 · Member rate